Acute Coronary Syndrome KCMC

Acute Coronary Syndrome Clinical Trial

Official title:

Community and Physician Perceptions of Chest Pain and Prevalence of Acute Coronary Syndrome Among HIV-infected and -Uninfected Patients in Moshi, Tanzania

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04563546
• Other study ID #: Pro00090902
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2023
• Est. completion date: October 1, 2024

Study information

• Verified date: September 2023
• Source: Duke University
• Contact: Julian Hertz, MD
• Phone: 919-681-0196
• Email: julian.hertz[@]duke.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to develop a quality improvement intervention to address barriers to evidence-based acute coronary syndrome (ACS) care in northern Tanzania. Patients who presented to Kilimanjaro Christian Medical Center (KCMC) will be asked to complete a survey about barriers and facilitators of health care. In addition the survey will be administered to all providers, policymakers, and administrators participating in in-depth interviews. Data from this survey will be used to develop a quality improvement intervention that will be piloted by KCMC staff. Six months after the pilot program is implemented providers, patients, and administrators will be interviewed for their perspectives on the program.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. completion date: October 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years or older

• symptoms related to acute coronary syndrome

• myocardial infarction

• clinically sober

• able to communicate in Swahili or English

Exclusion Criteria:

• medically unstable

• have a deteriorating condiction

• too critically ill to participate

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Syndrome

Intervention

Other:
• Quality Improvement
A quality improvement intervention including reminders, care protocols, and text messages to improve care of myocardial infarction in the KCMC ED

Locations

Country	Name	City	State
United States	Duke University Hospital	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acceptability as measured by the Acceptability of Intervention Measure (AIM)	The AIM tool is a 4-question survey that evaluates the acceptability of an intervention. Responses to each question are on a 5-point Likert Scale (Strongly Agree=5, Agree=4, Neutral=3, Disagree=2, Strongly Disagree=1). Responses of "Strongly Agree" (5) and "Agree" (4) are considered to indicate a more acceptable intervention. The responses to each question will be averaged together to give an acceptability score between 1 and 5 for each respondent. The primary outcome will be the overall mean acceptability score among respondents. A mean acceptability score >= 4 will be considered to indicate acceptability.	Initial ED visit (baseline)
Secondary	Patients presenting with chest pain or shortness of breath who undergo ECG and cardiac biomarker testing during their ED stay	Percentage of patients with these symptoms who undergo ECG and cardiac biomarker testing	Initial ED visit (baseline)
Secondary	Patients with ACS taking aspirin 30 days after enrollment	Percentage of patients taking aspiring at 30 days	30 days after enrollment
Secondary	Survival of ACS patients at 30 days after enrollment	Percentage of patients who have survived at 30 days	30 days after enrollment
Secondary	Aspirin administration	Percent of ED patients diagnosed with acute coronary syndrome receiving aspirin.	Initial ED visit (baseline)